1. Regulation of TLR4 expression mediates the attenuating effect of erythropoietin on inflammation and myocardial fibrosis in rat heart
   Fei Liu et al, 2018, International Journal of Molecular Medicine CrossRef
2. JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors
   Takeshi Wakashima et al, 2020, American Journal of Physiology-Renal Physiology CrossRef
3. The percentage of circulating fibrocytes is associated with increased morbidity of pulmonary hypertension in patients on hemodialysis
   Xing Liu et al, 2024, Seminars in Dialysis CrossRef
4. Erythropoietin reduces collagen deposition after myocardial infarction but does not improve cardiac function
   Fernanda Gallinaro Pessoa et al, 2018, Canadian Journal of Physiology and Pharmacology CrossRef
5. Erythropoietin Suppresses the Hepatic Fibrosis Caused by Thioacetamide: Role of the PI3K/Akt and TLR4 Signaling Pathways
   Marawan A. Elbaset et al, 2023, Oxidative Medicine and Cellular Longevity CrossRef
6. Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)
   Megan L. Noonan et al, 2020, Physiological Reports CrossRef
7. Elevated circulating fibrocyte levels in hemodialysis‐dependent end‐stage renal disease patients
   Xinjian Li et al, 2021, Hemodialysis International CrossRef
8. Role of Circulating Fibrocytes in Cardiac Fibrosis
   Rong-Jie Lin et al, 2016, Chinese Medical Journal CrossRef
9. Advances in Understanding the Effects of Erythropoietin on Renal Fibrosis
   Yangyang Zhang et al, 2020, Frontiers in Medicine CrossRef
10. Delayed treatment with erythropoietin attenuates renal fibrosis in mouse model of unilateral ureteral obstruction
    Akihiro Nishida et al, 2024, International Journal of Urology CrossRef
11. Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma
    Vanessa Desantis et al, 2018, Annals of Hematology CrossRef
12. Anti-fibrotic potential of erythropoietin signaling on bone marrow derived fibrotic cell
    Yasunori Iwata et al, 2021, BMC Nephrology CrossRef
13. Pleiotropic and Renoprotective Effects of Erythropoietin Beta on Experimental Diabetic Nephropathy Model
    Zehra Eren et al, 2016, Nephron CrossRef
14. Cytoprotective effects of erythropoietin: What about the lung?
    Liasmine Haine et al, 2021, Biomedicine & Pharmacotherapy CrossRef
15. Key Genetic Components of Fibrosis in Diabetic Nephropathy: An Updated Systematic Review and Meta-Analysis
    Maria Tziastoudi et al, 2022, International Journal of Molecular Sciences CrossRef
16. Anemia and Hypoxia Impact on Chronic Kidney Disease Onset and Progression: Review and Updates
    Elmukhtar Habas et al, 2023, Cureus CrossRef
17. Anemia in Chronic Kidney Disease Patients: An Update
    Elmukhtar Habas et al, 2022, Ibnosina Journal of Medicine and Biomedical Sciences CrossRef
18. The hypoxia-inducible factor-α prolyl hydroxylase inhibitor FG4592 ameliorates renal fibrosis by inducing the H3K9 demethylase JMJD1A
    Takeshi Ike et al, 2022, American Journal of Physiology-Renal Physiology CrossRef
19. Erythropoietin Ameliorates Ischemia/Reperfusion-Induced Acute Kidney Injury via Inflammasome Suppression in Mice
    Jihye Kwak et al, 2020, International Journal of Molecular Sciences CrossRef